Boston Scientific posts positive Watchman data

Courtesy of Boston Scientific

Boston Scientific's ($BSX) Watchman atrial fibrillation device improved patient quality of life over drug therapy, according to early results from its pivotal trial. The device, designed to prevent strokes in a-fib patients, bested warfarin in patient questionnaires, posting higher numbers in physical quality of life and mental health in the PROTECT AF study. Boston Scientific is in the midst of gathering data to support a PMA application with the FDA, and Watchman is already CE marked overseas to treat atrial fibrillation and protect against strokes. News

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.